PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case

US Supreme Court denies J&J petition seeking review of South Carolina’s $124m judgment related to Risperdal marketing, giving state unfair trade practice laws a boost.

More from Legal & IP

More from Pink Sheet